Join Growin Stock Community!

Crescent biopharma, inc.CBIO.US Overview

US StockHealthcare
(No presentation for CBIO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CBIO AI Insights

CBIO Overall Performance

CBIO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CBIO Recent Performance

-3.56%

Crescent biopharma, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CBIO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CBIO Key Information

CBIO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CBIO Profile

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

Price of CBIO

CBIO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CBIO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.03
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
47.48%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.03
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
47.48%

  • When is CBIO's latest earnings report released?

    The most recent financial report for Crescent biopharma, inc. (CBIO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CBIO's short-term business performance and financial health. For the latest updates on CBIO's earnings releases, visit this page regularly.

  • How much debt does CBIO have?

    As of the end of the reporting period, Crescent biopharma, inc. (CBIO) had total debt of 1.74M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CBIO have?

    At the end of the period, Crescent biopharma, inc. (CBIO) held Total Cash and Cash Equivalents of 133.37M, accounting for 0.96 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CBIO's EPS continuing to grow?

    According to the past four quarterly reports, Crescent biopharma, inc. (CBIO)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.27. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CBIO?

    Crescent biopharma, inc. (CBIO)'s Free Cash Flow (FCF) for the period is -18.13M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 193.37% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CBIO?

    The latest valuation data shows Crescent biopharma, inc. (CBIO) has a Price-To-Earnings (PE) ratio of -3.25 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.